Back to Browse Journals » Vascular Health and Risk Management » Volume 8

Ezetimibe therapy: mechanism of action and clinical update

Authors Phan BAP, Dayspring TD, Toth PP

Received 7 May 2012

Accepted for publication 23 May 2012

Published 3 July 2012 Volume 2012:8 Pages 415—427


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Binh An P Phan,1 Thomas D Dayspring,2 Peter P Toth3

1Division of Cardiology, Loyola University Medical Center, Maywood, IL, USA; 2Foundation for Health Improvement and Technology, Wayne, NJ, USA; 3CGH Medical Center, Sterling, IL, USA

Abstract: The lowering of low-density lipoprotein cholesterol (LDL-C) is the primary target of therapy in the primary and secondary prevention of cardiovascular events. Although statin therapy is the mainstay for LDL-C lowering, a significant percentage of patients prescribed these agents either do not achieve targets with statin therapy alone or have partial or complete intolerance to them. For such patients, the use of adjuvant therapy capable of providing incremental LDL-C reduction is advised. One such agent is ezetimibe, a cholesterol absorption inhibitor that targets uptake at the jejunal enterocyte brush border. Its primary target of action is the cholesterol transport protein Nieman Pick C1 like 1 protein. Ezetimibe is an effective LDL-C lowering agent and is safe and well tolerated. In response to significant controversy surrounding the use and therapeutic effectiveness of this drug, we provide an update on the biochemical mechanism of action for ezetimibe, its safety and efficacy, as well as the results of recent randomized studies that support its use in a variety of clinical scenarios.

Keywords: bile, coronary artery disease, ezetimibe, low-density lipoprotein cholesterol, Nieman pick C1 like 1 protein, statin

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at:

Readers of this article also read:

The landscape of alternative splicing in cervical squamous cell carcinoma

Guo P, Wang D, Wu J, Yang J, Ren T, Zhu B, Xiang Y

OncoTargets and Therapy 2015, 8:73-79

Published Date: 22 December 2014

Clinical significance of UGT1A1 gene polymorphisms on irinotecan-based regimens as the treatment in metastatic colorectal cancer

Li MM, Wang ZH, Guo J, Liu J, Li CZ, Liu L, Shi H, Liu LY, Li HH, Xie C, Zhang X, Sun WW, Fang S, Bi X

OncoTargets and Therapy 2014, 7:1653-1661

Published Date: 23 September 2014

How are patients with type 2 diabetes and renal disease monitored and managed? Insights from the observational OREDIA study

Penfornis A, Blicklé JF, Fiquet B, Quéré S, Dejager S

Vascular Health and Risk Management 2014, 10:341-352

Published Date: 13 June 2014

Challenges for heart disease stem cell therapy

Hoover-Plow J, Gong Y

Vascular Health and Risk Management 2012, 8:99-113

Published Date: 17 February 2012

Doppler study of cerebral arteries in hypercholesterolemia

Farhoudi M, Mehrvar K, Aslanabadi N, Ghabili K, Baghmishe NR, Ilkhchoei F

Vascular Health and Risk Management 2011, 7:203-207

Published Date: 31 March 2011

Benefits of statin therapy and compliance in high risk cardiovascular patients

Joel A Lardizabal, Prakash C Deedwania

Vascular Health and Risk Management 2010, 6:843-853

Published Date: 23 September 2010

Effects of telmisartan on office and 24-hour ambulatory blood pressure: an observational study in hypertensive patients managed in primary care

Frederic Kontny, Terje Risanger, Arne Bye, et al

Vascular Health and Risk Management 2010, 6:31-38

Published Date: 15 January 2010

HbA1c is associated with severity of obstructive sleep apnea hypopnea syndrome in nondiabetic men

Nikolaos Papanas, Paschalis Steiropoulos, Evangelia Nena, et al

Vascular Health and Risk Management 2009, 5:751-756

Published Date: 8 September 2009

The interleukin-6 –174 G/C promoter polymorphism and arterial stiffness; the Rotterdam Study

Mark PS Sie, Francesco US Mattace-Raso, André G Uitterlinden, Pascal P Arp, Albert Hofman, et al

Vascular Health and Risk Management 2008, 4:863-869

Published Date: 8 August 2008